NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
The last earnings update was 6 days ago.
Discounted Cash Flow Calculation for DB:0N6 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
DB:0N6 DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
NOXXON Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
NOXXON Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NOXXON Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if NOXXON Pharma is high growth as no earnings estimate data is available.
NOXXON Pharma's revenue is expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NOXXON Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Aram Mangasarian has been the Chief Executive Officer and Member of Executive Board at NOXXON Pharma AG since July 1, 2015 and served as its has been Chief Business Officer since May 18, 2010 and serves as its Member of Executive Board. Dr. Mangasarian is responsible for corporate and business development activities for NOXXON. He has more than 10 years of business development and strategic planning experience within the biotechnology and pharmaceutical industry. He served as Vice President of Business Development of Novexel SA. Dr. Mangasarian joined Novexel SA group from another French firm, ExonHit Therapeutics SA, a publicly traded French drug discovery and development company, where he spent over five years in business development, most recently as Vice President of Business Development. During this time, Dr. Mangasarian identified strategic partners, negotiated alliances and was responsible for marketing and sales of research products. He led the team that built strategic alliances and negotiated research agreements with a number of pharmaceutical companies. A key part of his role at ExonHit was the development of commercialization strategies. Dr. Mangasarian concluded a number of licensing and research agreements and prepared Novexel SA towards IPO. During his time in the laboratory of Didier Trono, he led two different teams in research projects in virology. He has contributed to several scientific publications including Nature Cell Biology and the Journal of Virology. Prior to ExonHit, he held a postdoctoral fellowship at The University of Geneva Medical School in the Department of Genetics and Microbiology from 1997 to 1999. He holds B.S. BioChemistry, Molecular Biology, English from University of Wisconsin-Madison in the year 1987-1992. As graduate of the University of California, San Diego, he earned his PhD in the Department of Biology by conducting research on HIV in the year 1992-1997. He holds an MBA in Business, from Insead in the year 1999.
Aram's compensation has increased whilst company is loss making.
Aram's remuneration is lower than average for companies of similar size in Germany.
CEO & Member of Management Board
Chief Medical Officer & Member of Management Board
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the NOXXON Pharma board of directors is about average.
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.